Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 10/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18632542 | 0.86 | SCN5A (0.61) | SCN5ANOTUMALDH1A1 | |
| SCHEMBL20772490 | 0.77 | SCN5A (0.51) | SCN5ANOTUMPRMT5WDR77 | |
| SCHEMBL5254089 | 0.77 | SCN5A (0.48) | SCN5ANOTUM | |
| SCHEMBL18632525 | 0.76 | SCN5A (0.51) | SCN5ANOTUMGSK3B | |
| SCHEMBL3793191 | 0.75 | SCN5A (0.43) | SCN5ANOTUMALDH1A1 | |
| SCHEMBL18632513 | 0.74 | SCN5A (0.49) | SCN5ANOTUM | |
| SCHEMBL20772287 | 0.73 | NOTUM (0.39) | SCN5ANOTUMGSK3BGSK3ATLR8 | |
| SCHEMBL18655673 | 0.73 | SCN5A (0.44) | SCN5ANOTUM | |
| SCHEMBL406976 | 0.73 | SCN5A (0.48) | SCN5ANOTUMGSK3BGSK3A | |
| SCHEMBL6724420 | 0.73 | SCN5A (0.55) | SCN5ANOTUMPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575114-B2 | SGLT-2 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110237527-A1 | SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| EP-1333031-A1 | BICYCLIC TRIAZOLONE DERIVATIVES AND HERBICIDES CONTAINING THE SAME | Sumitomo Chemical Takeda Agro Company, Limited (JP) | 2003-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237527-A1 | SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | SLC5A2, SLC5A1, SLC10A1 | SCN5A 692/4885NOTUM 1165/4885PARP1 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.